Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Population Trends in Incidence of Second Malignant Neoplasm and Cause-Specific Mortality in Patients with Multiple Myeloma

Luciano J. Costa, MD PhD, Kelly N. Godby, MD, Saurabh Chhabra, MD, Robert Frank Cornell, MD, Parameswaran Hari, MD MRCP, MS, Smita Bhatia, MDMPH

Blood (2017) 130 (Supplement 1): 682.

https://doi.org/10.1182/blood.V130.Suppl_1.682.682

Published: 2017

Journal Articles

Acquired Factor X Deficiency in Light Chain (AL) Amyloidosis Is Rare and Associated with Advanced Disease

Gina Patel, Parameswaran Hari, MD MRCP, MS, Aniko Szabo, PhD, Rein Lisa, Lisa M. Baumann Kreuziger, MD MS, Saurabh Chhabra, MD, Binod Dhakal, MBBS, Anita D'Souza, MBBS

Blood (2017) 130 (Supplement 1): 2363.

https://doi.org/10.1182/blood.V130.Suppl_1.2363.2363

Published: 2017

Journal Articles

A Comparison between 3 Staging Systems in Multiple Myeloma Using the Center for International Blood and Marrow Transplant Research (CIBMTR) Database

Emma Scott, Parameswaran Hari, MD MRCP, MS, Sathish Kumar, Raphael Fraser, Omar Davila, Yago Nieto, MD PhD, Tomer M Mark, MDMSc, Shaji K Kumar, MD, Cristina J. Gasparetto, MD, Anita D'Souza, MBBS

Blood (2017) 130 (Supplement 1): 3042.

https://doi.org/10.1182/blood.V130.Suppl_1.3042.3042

Published: 2017

Journal Articles

Duration of Therapy (DOT) and Time to Next Therapy (TTNT) of Bortezomib, Carfilzomib and Ixazomib Combinations with Lenalidomide/Dexamethasone (VRd, KRd, IRd) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Clinical Practice in the United States Vs Clinical Trial Experience

Ajai Chari, MD, Dorothy Romanus, Katarina Luptakova, MD, Aditya Raju, MS, Eileen Farrelly, MPH, Marlo Blazer, PharmD, Tomas Skacel, MD, Parameswaran Hari, MD MRCP, MS

Blood (2017) 130 (Supplement 1): 1818.

https://doi.org/10.1182/blood.V130.Suppl_1.1818.1818

Published: 2017

Journal Articles

Ixazomib for Chronic Graft-Versus-Host Disease (cGVHD) Prophylaxis in Patients Undergoing Allogeneic Transplantation (alloHCT): Preliminary Results of a Phase I/II Study

Saurabh Chhabra, MD, Parameswaran Hari, MD MRCP, MS, Alexis Visotcky, Nirav N Shah, MD, J. Douglas Rizzo, MD, Wael Saber, MD MS, Anita D'Souza, MBBS, Binod Dhakal, MBBS, Ashish Anshu, MS, PhD, Robert Thompson, Timothy S. Fenske, MD, Bronwen E. Shaw, PhD MRCP, FRCPath, William R. Drobyski, MD, Marcelo C. Pasquini, MD, Mehdi Hamadani, MD

Blood (2017) 130 (Supplement 1): 1974.

https://doi.org/10.1182/blood.V130.Suppl_1.1974.1974

Published: 2017

Journal Articles

Lenalidomide Maintenance for Patients with Newly Diagnosed Multiple Myeloma Post Autologous Stem Cell Transplant: A Comparison of Real-World Treatment Outcomes and Costs

Parameswaran Hari, MD MRCP, MS, Brian Ung, PharmD, Safiya Abouzaid, MPH, PharmD, Quanhong Ni, MS, Kejal Parikh, BSPharm, MS, Amit Agarwal, MD PhD

Blood (2017) 130 (Supplement 1): 2189.

https://doi.org/10.1182/blood.V130.Suppl_1.2189.2189

Published: 2017

Journal Articles

Revised-International Staging System (R-ISS) Is Independently Predictive and Prognostic for Early Relapse (<24 months) after Upfront Autologous Hematopoietic Cell Transplantation (AHCT) for Newly Diagnosed Multiple Myeloma (MM

Sathish Kumar, Anita D'Souza, MBBS, Emma C. Scott, MD, Raphael Fraser, Omar Davila, Cristina J. Gasparetto, MD, Shaji K Kumar, MD, Tomer M Mark, MDMSc, Yago Nieto, MD PhD, Parameswaran Hari, MD MRCP, MS

Blood (2017) 130 (Supplement 1): 2024.

https://doi.org/10.1182/blood.V130.Suppl_1.2024.2024

Published: 2017

Journal Articles

Haploidentical Hematopoietic Cell Transplantation Followed By Donor Natural Killer Cell Infusion and Sirolimus Maintenance Can Successfully Treat Patients with High-Risk Ewing Sarcoma

Monica Thakar, MD, Meghen Browning, MD, Parameswaran Hari, MD MRCP, MS, John Charlson, MD, Amy Newman, PhD, Brent R. Logan, PhD, Nathan Schloemer, MD, Michael Kelly, MD PhD, Bryon Johnson, PhD, Subramaniam Malarkannan, PhD, Carolyn A. Keever-Taylor, DPhil

Blood (2017) 130 (Supplement 1): 4525.

https://doi.org/10.1182/blood.V130.Suppl_1.4525.4525

Published: 2017

Journal Articles

Using "Big-Data" to Evaluate in-Hospital Morbidity and Mortality in Systemic Light Chain (AL) Amyloidosis after High Dose Therapy and Autologous Stem Cell Transplant (HDT/ASCT)

Binod Dhakal, MBBS, Xinran Qi, Guru Subramanian Guru Murthy, MBBS, Ravi Narra, MD, Aniko Szabo, PhD, Saurabh Chhabra, MD, Anita D'Souza, MBBS, Parameswaran Hari, MD MRCP, MS

Blood (2017) 130 (Supplement 1): 2170.

https://doi.org/10.1182/blood.V130.Suppl_1.2170.2170

Published: 2017

Journal Articles

Versican (VCAN) Proteolysis Predicts T-Cell Infiltration in Myeloma Bone Marrow Post- Autologous Stem Cell Transplant (ASCT)

Adam Pagenkopf, Binod Dhakal, MBBS, Chelsea L. Hope, PhD, Athanasios Papadas, MD, Michael G Johnson, PhD, Bradley Nagel, Elena Kurudza, Samik Partha, Bianca Ruffolo, Catherine Leith, MBBChir, Shigeki Miyamoto, PhD, Peiman Hematti, MD, Parameswaran Hari, MD MRCP, MS, Natalie Scott Callander, MD, Fotios Asimakopoulos, PhDMBBChir,

Blood (2017) 130 (Supplement 1): 1756.

https://doi.org/10.1182/blood.V130.Suppl_1.1756.1756

Published: 2017

Journal Articles

Incremental Financial and Health-Related Burden of Novel Drugs Used in the Treatment of Relapsed and/or Refractory Multiple Myeloma (RRMM): A Meta-Analysis of Phase III Randomized Controlled Trials (RCTs)

Binod Dhakal, MBBS, Ravi Narra, MD, Timothy Smunt, MBA, Angela Canadeo, Pharm D, Saurabh Chhabra, MD, Anita d'Souza, MBBS, MD, Bishal Gyawali, MD PhD, Parameswaran Hari, MD MRCP, MS, Saroj Niraula, MD

Blood (2017) 130 (Supplement 1): 3403.

https://doi.org/10.1182/blood.V130.Suppl_1.3403.3403

Published: 2017

Journal Articles

Phase 2 Study of Pembrolizumab during Lymphodepleted State after Autologous Hematopoietic Cell Transplantation in Multiple Myeloma Patients

Attaphol Pawarode, MD, Anita D'Souza, MBBS, Marcelo C. Pasquini, MD, Bryon Johnson, PhD, Thomas Braun, PhD, Binod Dhakal, MBBS, Mehdi Hamadani, MD, John M. Magenau, MD, Nirav N Shah, MD, Mary Mansour Riwes, DO, Brian Parkin, MD, Pavan Reddy, MD, Parameswaran Hari, MD MRCP, MS

Blood (2017) 130 (Supplement 1): 339.

https://doi.org/10.1182/blood.V130.Suppl_1.339.339

Published: 2017

Journal Articles

Prophylactic Natural Killer Cell Immunotherapy Following HLA-Haploidentical Hematopoietic Cell Transplantation Prevents Relapse and Improves Survival in Patients with High-Risk Hematological Malignancies

Monica Thakar, MD, Parameswaran Hari, MD MRCP, MS, David G. Maloney, MD PhD, Carolyn A. Keever-Taylor, PhD, Lori Jones, PhD, Shelly Heimfeld, PhD, Rainer F. Storb, MD, Brenda M. Sandmaier, MD

Blood (2016) 128 (22): 1161.

https://doi.org/10.1182/blood.V128.22.1161.1161

Published: 2016

Journal Articles

Checkpoint Blockade for Treatment of Relapsed Lymphoma Following Allogeneic Hematopoietic Cell Transplant: Use May be Complicated By Onset of Severe Acute Graft Versus Host Disease

Blood (2016) 128 (22): 1163.

https://doi.org/10.1182/blood.V128.22.1163.1163

Published: 2016

Journal Articles

Autologous Hematopoietic Cell Transplantation in Patients with Multiple Myeloma: IMPACT of Age

Binod Dhakal, MDMS, Ariel Nelson, MD, Guru Subramanian Guru Murthy, MD, Raphael Fraser, PhD, Daniel Eastwood, Mehdi Hamadani, MD, Anita D'Souza, MBBS, MD, Parameswaran Hari, MD MRCP, MS

Blood (2016) 128 (22): 3456.

https://doi.org/10.1182/blood.V128.22.3456.3456

Published: 2016

Journal Articles

Comparison of Autologous Hematopoietic Cell Transplant (autoHCT), Bortezomib, Lenalidomide (Len) and Dexamethasone (RVD) Consolidation with Len Maintenance (ACM), Tandem Autohct with Len Maintenance (TAM) and Autohct with Len Maintenance (AM) for up-Front Treatment of Patients with Multiple Myeloma (MM): Primary Results from the Randomized Phase III Trial of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0702 - StaMINA Trial)

Blood (2016) 128 (22): LBA-1.

https://doi.org/10.1182/blood.V128.22.LBA-1.LBA-1

Published: 2016

Journal Articles

Carfilzomib Plus High Dose Melphalan Conditioning Prior to Autologous Hematopoietic Cell Transplantation Followed By Carfilzomib Maintenance in Patients with Relapsed Multiple Myeloma

Luciano J. Costa, MD PhD, Heather Landau, MD, Saurabh Chhabra, MD, Parameswaran Hari, MD MRCP, MS, Donna Salzman, MD, Ayman Saad, MD, Racquel Innis-Shelton, MD, Mehdi Hamadani, MD, Roni Tamari, MD, Kelly N. Godby, MD, Vladimir Petrovic, Lisa Williams, RN, Evelyn Orlando, Pamela M Dixon, RN, Sergio A. Giralt, MD

Blood (2016) 128 (22): 4630.

https://doi.org/10.1182/blood.V128.22.4630.4630

Published: 2016

Journal Articles

Longer Time to Best Response and Depth of Response Are Associated with Improved Duration of Best Achieved Response and Progression-Free Survival (PFS): Post-Hoc Analysis of Phase 3 Tourmaline-MM1 Trial in Relapsed/Refractory Multiple Myeloma (RRMM)

Laurent Garderet, MD PhD, Jacob P. Laubach, MD, Anne-Marie Stoppa, MD, Parameswaran Hari, MD MRCP, MS, Michele Cavo, MD, Heinz Ludwig, MD, Maria-Victoria Mateos, MD PhD, Katarina Luptakova, Jianchang Lin, PhD, Helgi van de Velde, MD PhD, Deborah Berg, RN, MSN, Philippe Moreau, Paul G. Richardson, MD

Blood (2016) 128 (22): 2134.

https://doi.org/10.1182/blood.V128.22.2134.2134

Published: 2016

Journal Articles

CAR-T Cell Production Using the Clinimacs ® Prodigy System

Fenlu Zhu, PhD, Nirav N. Shah, MD MSHP, Huiqing Xu, MD, Dina Schneider, Rimas Orentas, PhD, Boro Dropulic, Parameswaran Hari, MD MRCP, MS, Carolyn A. Keever-Taylor, PhD

Blood (2016) 128 (22): 5724.

https://doi.org/10.1182/blood.V128.22.5724.5724

Published: 2016

Journal Articles

Impact of Routine Surveillance Imaging on Outcomes in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing Autologous Hematopoietic Cell Transplantation (auto-HCT)

Narendranath Epperla, MD, Namrata Shah, MD, Kristin Richardson, MD, Jonathan Kapke, DO, George Carrum, MD, Parameswaran Hari, MD MRCP, MS, Mehdi Hamadani, MD, Sai Ravi Pingali, MD, Reem Karmali, MD MS, Timothy S. Fenske, MD

Blood (2015) 126 (23): 4360.

https://doi.org/10.1182/blood.V126.23.4360.4360

Published: 2015

NARROW

Population Trends in Incidence of Second Malignant Neoplasm and Cause-Specific Mortality in Patients with Multiple Myeloma

Acquired Factor X Deficiency in Light Chain (AL) Amyloidosis Is Rare and Associated with Advanced Disease

A Comparison between 3 Staging Systems in Multiple Myeloma Using the Center for International Blood and Marrow Transplant Research (CIBMTR) Database

Duration of Therapy (DOT) and Time to Next Therapy (TTNT) of Bortezomib, Carfilzomib and Ixazomib Combinations with Lenalidomide/Dexamethasone (VRd, KRd, IRd) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Clinical Practice in the United States Vs Clinical Trial Experience

Ixazomib for Chronic Graft-Versus-Host Disease (cGVHD) Prophylaxis in Patients Undergoing Allogeneic Transplantation (alloHCT): Preliminary Results of a Phase I/II Study

Lenalidomide Maintenance for Patients with Newly Diagnosed Multiple Myeloma Post Autologous Stem Cell Transplant: A Comparison of Real-World Treatment Outcomes and Costs

Revised-International Staging System (R-ISS) Is Independently Predictive and Prognostic for Early Relapse (<24 months) after Upfront Autologous Hematopoietic Cell Transplantation (AHCT) for Newly Diagnosed Multiple Myeloma (MM

Haploidentical Hematopoietic Cell Transplantation Followed By Donor Natural Killer Cell Infusion and Sirolimus Maintenance Can Successfully Treat Patients with High-Risk Ewing Sarcoma

Using "Big-Data" to Evaluate in-Hospital Morbidity and Mortality in Systemic Light Chain (AL) Amyloidosis after High Dose Therapy and Autologous Stem Cell Transplant (HDT/ASCT)

Versican (VCAN) Proteolysis Predicts T-Cell Infiltration in Myeloma Bone Marrow Post- Autologous Stem Cell Transplant (ASCT)

Incremental Financial and Health-Related Burden of Novel Drugs Used in the Treatment of Relapsed and/or Refractory Multiple Myeloma (RRMM): A Meta-Analysis of Phase III Randomized Controlled Trials (RCTs)

Phase 2 Study of Pembrolizumab during Lymphodepleted State after Autologous Hematopoietic Cell Transplantation in Multiple Myeloma Patients

Prophylactic Natural Killer Cell Immunotherapy Following HLA-Haploidentical Hematopoietic Cell Transplantation Prevents Relapse and Improves Survival in Patients with High-Risk Hematological Malignancies

Checkpoint Blockade for Treatment of Relapsed Lymphoma Following Allogeneic Hematopoietic Cell Transplant: Use May be Complicated By Onset of Severe Acute Graft Versus Host Disease

Autologous Hematopoietic Cell Transplantation in Patients with Multiple Myeloma: IMPACT of Age

Carfilzomib Plus High Dose Melphalan Conditioning Prior to Autologous Hematopoietic Cell Transplantation Followed By Carfilzomib Maintenance in Patients with Relapsed Multiple Myeloma

Longer Time to Best Response and Depth of Response Are Associated with Improved Duration of Best Achieved Response and Progression-Free Survival (PFS): Post-Hoc Analysis of Phase 3 Tourmaline-MM1 Trial in Relapsed/Refractory Multiple Myeloma (RRMM)

CAR-T Cell Production Using the Clinimacs ® Prodigy System

Impact of Routine Surveillance Imaging on Outcomes in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing Autologous Hematopoietic Cell Transplantation (auto-HCT)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only